Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Disufenton sodium (NXY-059) 是一种神经保护剂 phenylbutynitrone 的衍生物,具有强大的自由基清除能力。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 318 | 现货 | ||
10 mg | ¥ 493 | 现货 | ||
25 mg | ¥ 1,080 | 现货 | ||
50 mg | ¥ 1,850 | 现货 | ||
100 mg | ¥ 3,280 | 现货 | ||
200 mg | ¥ 4,930 | 现货 | ||
500 mg | ¥ 7,580 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 349 | 现货 |
产品描述 | Disufenton sodium (NXY-059), a new-type nitrone, exhibits potently neuroprotective effects. |
体外活性 | NXY-059 is more soluble than the spin trapping agent α-phenyl-N-tert-butyl nitrone (PBN). [1] In an in vitro blood-brain barrier (BBB) model, 250 mM of NXY-059 administered at the onset or up to 4 h after oxygen glucose deprivation (OGD) produces a significant reduction in the increased BBB permeability caused by OGD. Furthermore, OGD produces a huge influx of tissue plasminogen activator across the BBB, which is substantially reduced by NXY-059. [2] |
体内活性 | NXY-059 reduces infarct volume in rats subjected to 2 hours of middle cerebral artery occlusion in a dose-dependent manner. At equimolar doses (3.0 mg/kg for NXY-059 and 1.4 mg/kg for PBN), NXY-059 is more efficacious than PBN. Similar results are obtained when a recovery period of 7 days is allowed. The window of therapeutic opportunity for NXY-059 is 3 to 6 hours after the start of recirculation. [1] NXY-059, a free radical-trapping agent, has a substantial protective effect, lessening the disability caused by an experimentally induced stroke in a primate species. NXY-059 treatment reduces the overall amount of brain damage by >50% of saline-treatment values, with similar levels of protection afforded to both white and gray matter. [3] Treatment with NXY-059 (50 mg/kg subcutaneous plus 8.8 mg/kg/h for 3 days subcutaneous delivered via implanted osmotic pumps) significantly decreases neurological impairment following intracerebral hemorrhage in rat, and reduces the neutrophil infiltrate observed 48 hours post-hemorrhage in the vicinity of the hematoma, and the number of TUNEL-positive cells 48 hours post-hemorrhage at the hematoma margin. [4] |
别名 | Cerovive, NXY059, OKN007, NXY-059, NXY 059 |
分子量 | 381.33 |
分子式 | C11H13NNa2O7S2 |
CAS No. | 168021-79-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 70 mg/mL (183.6 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 71 mg/mL (186.2 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 2.6224 mL | 13.112 mL | 26.224 mL | 65.56 mL |
5 mM | 0.5245 mL | 2.6224 mL | 5.2448 mL | 13.112 mL | |
10 mM | 0.2622 mL | 1.3112 mL | 2.6224 mL | 6.556 mL | |
20 mM | 0.1311 mL | 0.6556 mL | 1.3112 mL | 3.278 mL | |
50 mM | 0.0524 mL | 0.2622 mL | 0.5245 mL | 1.3112 mL | |
100 mM | 0.0262 mL | 0.1311 mL | 0.2622 mL | 0.6556 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Disufenton sodium 168021-79-2 Immunology/Inflammation Metabolism NF-Κb Reactive Oxygen Species Inhibitor Cerovive OKN-007 OKN 007 inhibit NXY059 Disufenton OKN007 NXY-059 NXY 059 inhibitor